26
total announcements
MARKSANS.NS · 15 min delayed
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange that Record date for the purpose of Dividend is 20-Aug-2026. The company has fixed Thursday, 20 August 2026 as the Record Date for determining eligibility of Members to receive final dividend for the financial year ended 31 March 2026.
Marksans Pharma Limited
Marksans Pharma Limited has announced its record date for determining eligibility of members to receive final dividend for the financial year ended 31 March 2026 as Thursday, 20 August 2026. The company has recommended a final dividend of ₹ 0.90/- (90%) per equity share of face value of ₹ 1/- each for the financial year ended 31 March 2026, subject to approval of members at the ensuing AGM.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding Outcome of Board Meeting held on July 03, 2026, where the Board approved the 34th Annual General Meeting and fixed the record date for final dividend for FY 2026.
Marksans Pharma Limited
Marksans Pharma Limited has informed the Exchange regarding the closure of the trading window for designated persons and their immediate relatives from July 1, 2026, until 48 hours after the declaration of unaudited financial results for the quarter ended June 30, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has submitted the machine-readable form/legible copy of its financial results for the quarter and year ended March 31, 2026, after initially submitting them in an incorrect format on May 26, 2026.
Marksans Pharma Limited
Marksans Pharma Limited has launched its 'Second 100 Day Campaign - Saksham Niveshak' to assist shareholders in claiming unclaimed dividends from FY2018-19 onwards, preventing their transfer to the Investor Education and Protection Fund (IEPF). The campaign, initiated based on an MCA directive, also encourages shareholders to update their KYC details, contact information, bank account details, and nominations. This initiative aims to enhance transparency and ensure direct claim processing for investors.